Renalytix uses cookies to improve your experience. We respect your privacy and are committed to protecting your personal data. Read Privacy Notice.
Investors KidneyIntelX

About Elise Wilfinger

This author has not yet filled in any details.
So far Elise Wilfinger has created 6 blog entries.

Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9

LONDON and SALT LAKE CITY, June 05, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter fiscal year 2023 financial results on Friday, June 9, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the


Read More
By |2024-02-21T11:26:28+00:0006.05.23|News|Comments Off on Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9

Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes

Model expected to accelerate deployment of KidneyIntelX across key U.S. regions with high rates of diabetic kidney disease and established insurance coverage LONDON and CHICAGO, May 25, 2023 (GLOBE NEWSWIRE) -- Renalytix (NASDAQ: RNLX) (LSE: RENX) , the first company to develop and commercialize an


Read More
By |2024-02-21T11:26:28+00:0005.25.23|News|Comments Off on Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes

New Published Real-World Evidence Shows KidneyIntelX™ Utility

Real-World Utility Data Demonstrates KidneyIntelX Optimizes Clinical Management in Early-Stage Chronic Kidney Disease Across Multiple Physician Specialties KidneyIntelX individualizes clinical decisions beginning at primary care where impacts of new therapies, blood pressure strategies and timely


Read More
By |2024-02-21T11:26:29+00:0004.19.23|News|Comments Off on New Published Real-World Evidence Shows KidneyIntelX™ Utility

Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting

In a clinical decision effectiveness study, KidneyIntelX classified more Black vs non-Black patients as high risk for progression of chronic kidney disease, resulting in increased prescription of SGLT2-inhibitor  drug therapy Additional study results illustrate how KidneyIntelX is aligned with the


Read More
By |2024-02-21T11:26:29+00:0004.12.23|News|Comments Off on Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting

Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results

LONDON and SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today


Read More
By |2024-02-21T11:26:30+00:0003.30.23|News|Comments Off on Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results

Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30

LONDON and SALT LAKE CITY, March 22, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that it will report its second quarter and first half fiscal year 2023 financial results on Thursday, March 30, 2023, before market open.


Read More
By |2024-02-21T11:26:30+00:0003.22.23|News|Comments Off on Renalytix to Report Second Quarter and First Half Fiscal Year 2023 Financial Results on March 30
Go to Top